ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Clinical Cooperative Groups Funding To Decrease 42.5 Mil.

October 11, 1985

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

December 26, 2014

Agency Approves Two Pairs Of Drugs and Diagnostic Tests

September 30, 2011

Craig Thompson Of Abramson Center Named President, CEO, Of Memorial Sloan-Kettering

September 3, 2010

Congress Insists On No Downward Negotiations; NCI May Drop 2000 To 300 Grants In FY 1991

November 9, 1990

McKay Retires As Fox Chase Executive, Is Succeeded By Donald Leedy As VP.

June 2, 2000